Are you guys really that dumb? They don’t use OS as the primary endpoint because it would be unethical to treat some patients with a revolutionary drug and let others die 10 months earlier based on chance. That’s why they have cross-over. The Sorafenib phase III clinical trial did the same thing against a placebo, and had 17.8 months OS versus 15.2 months for a PLACEBO (that means no active drug). It isn’t important you beat the comparator, its important you extend both populations’ OS ( because almost everyone is treated with the new drug) . Tivozanib extended the OS to 28.8 months versus sorafenibs 17.8 months. It is clearly better, and it’s a no brainer for the FDA to approve.